Ticker Details
Halozyme Therapeutics, Inc. Halozyme Therapeutics Inc is a biotechnology company. It is engaged in research on human enzymes that alter the extracellular matrix and tumor environment.
IPO Date:	March 16, 2004
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$8.35B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.39 | 2.13%
Avg Daily Range (30 D):	$1.19 | 1.59%
Avg Daily Range (90 D):	$1.04 | 1.47%

Institutional Daily Volume
Avg Daily Volume:	.98M
Avg Daily Volume (30 D):	1.62M
Avg Daily Volume (90 D):	1.79M

Trade Size
Avg Trade Size (Sh.):	104
Avg Trade Size (Sh.) (30 D):	57
Avg Trade Size (Sh.) (90 D):	63

Institutional Trades
Total Institutional Trades:	10,443
Avg Institutional Trade:	$3.1M
Avg Institutional Trade (30 D):	$5.91M
Avg Institutional Trade (90 D):	$5.16M
Avg Institutional Trade Volume:	.08M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$6.17M
Avg Closing Trade (30 D):	$21.71M
Avg Closing Trade (90 D):	$20.8M
Avg Closing Volume:	164.4K

News

Jan 28, 2026 @ 6:58 PM Halozyme Therapeutics Projects Sustained Growth We... Source: Vandana Singh

Dec 16, 2025 @ 6:17 PM Immunotherapy Breakthroughs Turn Cold GI Tumors Ho... Source: Prnewswire

Nov 5, 2025 @ 10:12 PM Renaissance Group Opens New $35M Position in Haloz... Source: Josh Kohn-Lindquist

Nov 5, 2025 @ 9:00 PM Acumen Pharmaceuticals to Report Third Quarter 202... Source: Acumen Pharmaceuticals

Oct 29, 2025 @ 3:00 PM argenx Presents New Data at AANEM and MGFA Highlig... Source: Argenx Se

Financials
	TTM	Q4 2025	FY 2025
Basic EPS	$2.64	$-1.16	$2.64
Diluted EPS	$2.56	$-1.12	$2.56
Revenue	$1.4B	$451.77M	$1.4B
Gross Profit	$1.17B	$373M	$1.17B
Net Income / Loss	$316.89M	$-141.59M	$316.89M
Operating Income / Loss	$469.01M	$-92.89M	$469.01M
Cost of Revenue	$228.77M	$78.77M	$228.77M
Net Cash Flow	$20.57M	$-283.24M	$20.57M
PE Ratio	27.48